B Hirschel

1.9k total citations · 1 hit paper
23 papers, 1.1k citations indexed

About

B Hirschel is a scholar working on Virology, Infectious Diseases and Emergency Medicine. According to data from OpenAlex, B Hirschel has authored 23 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Virology, 13 papers in Infectious Diseases and 4 papers in Emergency Medicine. Recurrent topics in B Hirschel's work include HIV Research and Treatment (13 papers), HIV/AIDS drug development and treatment (12 papers) and HIV/AIDS Research and Interventions (9 papers). B Hirschel is often cited by papers focused on HIV Research and Treatment (13 papers), HIV/AIDS drug development and treatment (12 papers) and HIV/AIDS Research and Interventions (9 papers). B Hirschel collaborates with scholars based in Switzerland, United States and Australia. B Hirschel's co-authors include Amalio Telenti, P Erb, Lionel Perrin, Hansjakob Furrer, Gilbert Greub, P Francioli, Markus Flepp, P Janin, Manuel Battegay and Peter M. Grob and has published in prestigious journals such as The Lancet, Neurology and Clinical Infectious Diseases.

In The Last Decade

B Hirschel

23 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study

2000 692 citations Gilbert Greub, Manuel Battegay et al. The Lancet profile →

Peers

Countries citing papers authored by B Hirschel

Since Specialization

Citations

This map shows the geographic impact of B Hirschel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B Hirschel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B Hirschel more than expected).

Fields of papers citing papers by B Hirschel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B Hirschel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B Hirschel. The network helps show where B Hirschel may publish in the future.

Co-authorship network of co-authors of B Hirschel

This figure shows the co-authorship network connecting the top 25 collaborators of B Hirschel. A scholar is included among the top collaborators of B Hirschel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B Hirschel. B Hirschel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Higher CNS Penetration-Effectiveness of Long-term Combination Antiretroviral Therapy Is Associated With Better HIV-1 Viral Suppression in Cerebrospinal Fluid 2012 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Alexia Cusini, Pietro Vernazza, Sabine Yerly, Laurent A. Décosterd, Bruno Ledergerber, Christoph A. Fux, (unknown), Nicolas Widmer, B Hirschel, (unknown), Matthias Cavassini, Thomas Klimkait, (unknown), (unknown), Milos Opravil, Huldrych F. Günthard	72
2	Rivastigmine for the Treatment of HIV-Associated Neurocognitive Disorders: A Randomized, Double-Blind, Placebo-Controlled, Crossover Pilot Study (S37.005) 2012 ·Neurology ·Samanta Simioni, Matthias Cavassini, Marc Michel, Jean‐Marie Annoni, Katia Iglesias, (unknown), Alexandra Calmy, Ezio Giacobini, B Hirschel, Renaud Du Pasquier	1
3	Implementation of Raltegravir in Routine Clinical Practice: Selection Criteria for Choosing This Drug, Virologic Response Rates, and Characteristics of Failures 2010 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Alexandra U. Scherrer, Viktor von Wyl, (unknown), Milos Opravil, Heiner C. Bucher, Aurélie Fayet, Laurent A. Décosterd, B Hirschel, (unknown), Sabine Yerly, Thomas Klimkait, Hansjakob Furrer, Bruno Ledergerber, Huldrych F. Günthard	15
4	Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy 2010 ·Gut ·(unknown), (unknown), Gillian Harcourt, E. Hammond, Silvana Gaudieri, Meri Gorgievski, Amalio Telenti, Olivia Keiser, Huldrych F. Günthard, B Hirschel, Matthias Hoffmann, Enos Bernasconi, Manuel Battegay, H Furrer, Paul Klenerman, Andri Rauch, (unknown)	35
5	How reliable is an undetectable viral load? 2009 ·HIV Medicine ·Christophe Combescure, N Vallier, Bruno Ledergerber, Matthias Cavassini, H Furrer, Andri Rauch, Manuel Battegay, Enos Bernasconi, Pietro Vernazza, B Hirschel, (unknown)	7
6	[Therapeutic education in the field of infection diseases: the example of HIV infection]. 2009 ·PubMed ·(unknown), Alexandra Calmy, Francesco Amati, (unknown), V. Schwarz, B Hirschel, A. Golay	2
7	Treatment interruption for convenience, cost cutting and toxicity sparing 2007 ·Current Opinion in HIV and AIDS ·Reto Nüesch, B Hirschel	3
8	A Prospective, Randomized Trial of Structured Treatment Interruption for Patients with Chronic HIV Type 1 Infection 2005 ·Clinical Infectious Diseases ·Peter Cardiello, Elly A. Hassink, Jintanat Ananworanich, Preeyaporn Srasuebkul, (unknown), Apicha Mahanontharit, Kiat Ruxrungtham, B Hirschel, Joep M. A. Lange, Praphan Phanuphak, D. A. Cooper	48
9	Traitement par cidofovir topique d’infections cutanées à papillomavirus humain, poxvirus et Herpes simplex virus chez des malades séropositifs pour le VIH 2004 ·Annales de Dermatologie et de Vénéréologie ·Laurence Toutous‐Trellu, B Hirschel, Vincent Piguet, Véronique Schiffer, J.‐H. Saurat, M. Péchère	24
10	Attenuated and Nonproductive Viral Transcription in the Lymphatic Tissue of HIV‐1–Infected Patients Receiving Potent Antiretroviral Therapy 2004 ·The Journal of Infectious Diseases ·Marek Fischer, Béda Joos, Joseph K. Wong, Peter Ott, Milos Opravil, B Hirschel, Rainer Weber, Huldrych F. Günthard, (unknown)	37
11	HumanImmunodeficiency Virus Type 1 Fitness Is a Determining Factor in ViralRebound and Set Point in ChronicInfection 2003 ·Journal of Virology ·Alexandra Trkola, Herbert Kuster, Christine Leemann, Claudia R. Ruprecht, Béda Joos, Amalio Telenti, B Hirschel, Rainer Weber, Sebastian Bonhoeffer, Huldrych F. Günthard	38
12	Residual Cell-Associated Unspliced HIV-1 Rna in Peripheral Blood of Patients on Potent Antiretroviral Therapy Represents Intracellular Transcripts 2002 ·Antiviral Therapy ·(unknown), Marek Fischer, Joseph K. Wong, Doris Russenberger, Béda Joos, Milos Opravil, B Hirschel, Alexandra Trkola, Herbert Kuster, Rainer Weber, Huldrych F. Günthard	60
13	Combined therapy with saquinavir, ritonavir and stavudine in moderately to severely immunosuppressed HIV‐infected protease inhibitor‐naive patients 2001 ·HIV Medicine ·Manuel Battegay, Pietro Vernazza, Enos Bernasconi, Markus Flepp, Pedram Sendi, P Erb, R Malinverni, (unknown), (unknown), Véronique Bédoucha, B Hirschel, (unknown)	2
14	Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study breakdown → 2000 ·The Lancet ·Gilbert Greub, (unknown), Manuel Battegay, Peter M. Grob, Lionel Perrin, Hansjakob Furrer, (unknown), P Erb, Katia Boggian, J-C Piffaretti, B Hirschel, P Janin, P Francioli, Markus Flepp, Amalio Telenti	692
15	Switch to an unusual amino acid at codon 215 of the HIV-1 reverse transcriptase gene in seroconverters infected with zidovudine resistant variants. 1998 ·UCL Discovery (University College London) ·Sabine Yerly, (unknown), Sabine Kinloch‐de Loes, B Hirschel, Delphyne Descamps, (unknown), Lionel Perrin	3
16	Antiretroviral therapy: a guide to the most important trials. 1997 ·PubMed ·Olivier Rutschmann, B Hirschel	6
17	Capnocytophaga canimorsus Sepsis Complicated by Myocardial Infarction in Two Patients with Normal Coronary Arteries 1996 ·Clinical Infectious Diseases ·(unknown), J Gubler, Stephan Harbarth, B Hirschel	16
18	[Reversal of positive serology for human immunodeficiency virus (HIV). Apropos of 2 case reports]. 1988 ·PubMed ·Luc Perrin, Rudolf H. Zubler, B Hirschel, (unknown), Oscar Daniel Salomón, (unknown), (unknown)	5
19	Air in the bones: multifocal anaerobic osteomyelitis associated with oat cell carcinoma. 1985 ·BMJ ·(unknown), Elizabeth F. Sheybani, B Hirschel, (unknown)	13
20	Cloning and analysis of the K1 capsule biosynthesis genes of Escherichia coli: lack of homology with Neisseria meningitidis group B DNA sequences 1983 ·Infection and Immunity ·(unknown), B Hirschel, G J Boulnois, J M Varley, F. A. Waldvogel, Kenneth N. Timmis	51

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact